BUZZ-Street View -India's Sun Pharma buying Checkpoint boosts its specialty portfolio, analysts say

Reuters03-11

** Shares of India's Sun Pharma SUN.NS climb 3% to 1,656.25 rupees

** SUN top pct gainer on pharma index .NIPHARM and second-biggest gainer on Nifty 50 .NSEI

** India's top drugmaker by revenue to acquire U.S.-based Checkpoint Therapeutics CKPT.O for $355 million

$1 BILLION OPPORTUNITY

** JP Morgan ("overweight", PT: 2,210 rupees) says Checkpoint acquisition "checks the boxes" as it gives SUN access to a US FDA approved skin cancer drug Unloxcyt, which has potential to become a $1 billion opportunity in US

** Adds, acquisition will bolster SUN's specialty offerings in skin cancer space, which has been one of its key focus areas

** BofA Securities ("neutral", PT: 1,940 rupees) says Unloxcyt has an advantage over rivals' drugs due to lower price, but says it awaits clarity on SUN's commercial strategy

** Motilal Oswal ("buy", PT: 1,895 rupees) says SUN is "on a spree to expand specialty portfolio" and Checkpoint's five cancer treatment assets to complement SUN's existing portfolio

(Reporting by Kashish Tandon in Bengaluru)

((Kashish.tandon@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment